Results 201 to 210 of about 88,842 (261)

Therapeutic role of plant bioactive compounds in atrazine-mediated neurotoxicity. [PDF]

Adv Neurotoxicol
Nwawuba SU, Mohammed KA, Loreto J, Ajayi BO, Barbosa NV, Aschner M, Adedara IA, Rocha JBT.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Movement Disorders Induced by Dopamine Blocking Agents

Seminars in Neurology, 2001
Movement disorders are frequently due to dopamine blocking agents (DBAs) prescribed for psychiatric illnesses. DBAs are sometimes also prescribed inappropriately for other maladies. These drugs can cause a wide variety of involuntary movements, sometimes in combination.
Kapil D Sethi
exaly   +3 more sources

Dopamine D2 receptor agents, but not dopamine D1, modify brain glucose metabolism

Brain Research, 1985
The effects of recently described selective dopamine D1 and D2 agonists and antagonists on brain glucose metabolism were studied using the 2-[14C]deoxyglucose autoradiographic technique. The administration of LY-141865 or YM-09151-2, which behave as a specific D2 agonist and antagonist respectively, modified brain glucose metabolism in a manner similar
Karl-Heinz Wiederhold
exaly   +3 more sources

Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents

ACS Chemical Neuroscience, 2018
More than 40 years of research and clinical practice have proven the effectiveness of dopamine receptor antagonists in the pharmacological treatment of tics. A blockade of the striatal dopamine-D2 receptors is mainly responsible for their tic-reducing effect.
Judith Buse, Veit Roessner
exaly   +3 more sources

Effects of alkylating agents on dopamine D3 receptors in rat brain: selective protection by dopamine

Brain Research, 1999
Dopamine D(3) receptors are structurally highly homologous to other D(2)-like dopamine receptors, but differ from them pharmacologically. D(3) receptors are notably resistant to alkylation by 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), which readily alkylates D(2) receptors. We compared EEDQ with N-(p-isothiocyanatophenethyl)spiperone (NIPS),
Kehong Zhang, Frank I Tarazi, Nora S Kula   +2 more
exaly   +3 more sources

Dopamine D3 receptor antagonists as therapeutic agents

Drug Discovery Today, 2005
The behavioral and pathophysiological role of the dopamine D(3) receptor, which was deduced from anatomical, lesion and drug treatment studies in the ten years following cloning of the receptor, indicated that its functions differed from those of the D(2) receptor.
Jeffrey N, Joyce, Mark J, Millan
openaire   +2 more sources

IV inotropic agents: dopamine, dobutamine, and amrinone

Critical Care Nurse, 1990
Three commonly used IV inotropic agents--dopamine, dobutamine, and amrinone--have been discussed in this article. Knowledge of their common mechanisms of action, individual actions, dosages, methods of preparation, precautions, and side effects can only help critical care nurses maintain or improve the quality of care given to patients receiving these ...
J, Budny, K, Anderson-Drevs
openaire   +2 more sources

Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT

Journal of Medicinal Chemistry, 1993
A novel series of dual-labeling D2 dopamine agents (labeled with either 18F or 123I for PET or SPECT imaging, respectively) was investigated. Two desired fluorinated and iodinated dopamine agents, FIDA1, (S)-(-)-2-(2-fluoroethoxy)-5-iodo-3-methoxy-N-[(1-ethyl-2- pyrrolidinyl)methyl]-benzamide, and FIDA2, (R)-(+)-2,3-dimethoxy-5-iodo-N-[(1-(4 ...
S, Chumpradit, M P, Kung, J, Billings, R, Mach, H F, Kung   +4 more
openaire   +2 more sources